PURPOSE: To evaluate regression rates after plaque radiotherapy and thermotherapy of uveal melanoma with chromosome 3 monosomy versus disomy. DESIGN: Noncomparative case series. PARTICIPANTS: Two hundred and seventy patients with uveal melanoma. METHODS: Fine needle aspiration biopsy was used at the time of plaque radiotherapy to sample tumor cells for genetic testing. MAIN OUTCOME MEASURES: Tumor thickness regression based on chromosome 3 status. RESULTS: At the time of plaque radiotherapy, the median tumor thickness was 4.0 mm for melanomas with chromosome 3 monosomy and 3.5 mm for those with disomy 3. The median tumor thickness (% original thickness) at 4, 8, 12, 15, and 18 months after radiotherapy for melanoma with monosomy 3 was 77%, 67%, 58%, 55%, and 50% and for those with disomy 3 was 82%, 70%, 69%, 67%, and 61%. The median monthly regression rate was 3.1% for tumors with monosomy 3 and 2.7% for those with disomy 3. The overall regression and monthly rate of regression was statistically greater at 12 months (P < 0.001) and 15 months (P = 0.003) for melanomas with monosomy 3 compared with disomy 3. CONCLUSIONS: Uveal melanomas with chromosome 3 monosomy showed faster and greater tumor thickness regression at 12 and 15 months after plaque radiotherapy and thermotherapy than melanomas with disomy 3.
PURPOSE: To evaluate regression rates after plaque radiotherapy and thermotherapy of uveal melanoma with chromosome 3 monosomy versus disomy. DESIGN: Noncomparative case series. PARTICIPANTS: Two hundred and seventy patients with uveal melanoma. METHODS: Fine needle aspiration biopsy was used at the time of plaque radiotherapy to sample tumor cells for genetic testing. MAIN OUTCOME MEASURES: Tumor thickness regression based on chromosome 3 status. RESULTS: At the time of plaque radiotherapy, the median tumor thickness was 4.0 mm for melanomas with chromosome 3 monosomy and 3.5 mm for those with disomy 3. The median tumor thickness (% original thickness) at 4, 8, 12, 15, and 18 months after radiotherapy for melanoma with monosomy 3 was 77%, 67%, 58%, 55%, and 50% and for those with disomy 3 was 82%, 70%, 69%, 67%, and 61%. The median monthly regression rate was 3.1% for tumors with monosomy 3 and 2.7% for those with disomy 3. The overall regression and monthly rate of regression was statistically greater at 12 months (P < 0.001) and 15 months (P = 0.003) for melanomas with monosomy 3 compared with disomy 3. CONCLUSIONS: Uveal melanomas with chromosome 3 monosomy showed faster and greater tumor thickness regression at 12 and 15 months after plaque radiotherapy and thermotherapy than melanomas with disomy 3.
Authors: Michael C Chappell; Devron H Char; Tia B Cole; J William Harbour; Kavita Mishra; Vivian K Weinberg; Theodore L Phillips Journal: Am J Ophthalmol Date: 2012-04-27 Impact factor: 5.258
Authors: Hakan Demirci; Fiorella Saponara; Adam Khan; Leslie M Niziol; Choonik Lee; James A Hayman; Grant Comer; David C Musch Journal: Middle East Afr J Ophthalmol Date: 2015 Jan-Mar
Authors: Joanna Kowal; Anna Markiewicz; Magdalena Dębicka-Kumela; Anna Bogdali; Boz Ena Romanowska-Dixon Journal: J Contemp Brachytherapy Date: 2018-12-28